View Older Stories View More Recent Stories

Jul 30, 2025 08:07AM Sarepta Therapeutics (SRPT) PT Raised to $18 at Bernstein

Jul 30, 2025 06:40AM Sarepta Therapeutics (SRPT) PT Raised to $19 at Mizuho

Jul 29, 2025 10:27AM Sarepta Therapeutics (SRPT) PT Raised to $17 at TD Cowen

Jul 29, 2025 10:05AM Barclays Upgrades Sarepta Therapeutics (SRPT) to Equalweight

Jul 29, 2025 09:37AM Oppenheimer Upgrades Sarepta Therapeutics (SRPT) to Outperform

Jul 29, 2025 08:41AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Jul 29, 2025 07:20AM Sarepta Therapeutics (SRPT) PT Raised to $15 at Piper Sandler

Jul 29, 2025 06:55AM Sarepta Therapeutics (SRPT) PT Raised to $50 at BMO Capital

Jul 29, 2025 06:37AM Sarepta Therapeutics (SRPT) PT Raised to $5 at H.C. Wainwright

Jul 29, 2025 05:42AM Sarepta Therapeutics (SRPT) call put ratio 1.7 calls to 1 put into FDA headlines

Jul 29, 2025 04:05AM Bernstein SocGen Group Starts Sarepta Therapeutics (SRPT) at Market Perform

Jul 29, 2025 03:19AM JPMorgan Upgrades Sarepta Therapeutics (SRPT) to Neutral

Jul 28, 2025 05:23PM Sarepta Therapeutics (SRPT) to resume trading at 5:40 PM ET

Jul 28, 2025 05:10PM FDA allows Sarepta to resume ELEVIDYS shipments for ambulatory patients

Jul 28, 2025 04:32PM FDA lifts voluntary hold on Sarepta gene therapy for walking DMD patients

Jul 28, 2025 04:20PM Sarepta Therapeutics (SRPT) Halted, News Pending

Jul 28, 2025 07:30AM Arrowhead receives $100 million milestone from Sarepta for ARO-DM1 study

Jul 28, 2025 07:04AM H.C. Wainwright Reiterates Sell, $0 PT on Sarepta (SRPT), 'see low likelihood of positive catalysts near-term'

Jul 28, 2025 02:52AM Barclays Downgrades Sarepta Therapeutics (SRPT) to Underweight

Jul 25, 2025 04:42PM Sarepta Therapeutics (SRPT) Tanks 36% After 3d Patient Death, SRPT Securities Class Action Pending; Investors With Substantial Losses And Persons With Knowledge Encouraged To Contact Hagens Berman

Jul 25, 2025 08:34AM Sarepta receives negative EU opinion for Duchenne gene therapy ELEVIDYS

Jul 25, 2025 06:37AM H.C. Wainwright Reiterates Sarepta (SRPT) at Sell, $0 price target, 'major blow to Sarepta'

Jul 25, 2025 06:28AM Sarepta's Elevidys Fails to Get EU Approval - Bloomberg

Jul 25, 2025 05:24AM Sarepta Therapeutics (SRPT) call put ratio 1 call to 1 put on 94K contracts

Jul 25, 2025 03:30AM JPMorgan Downgrades Sarepta Therapeutics (SRPT) to Underweight

Jul 24, 2025 03:16PM Sarepta Therapeutics (SRPT) Off Lows on Positive Chatter

Jul 24, 2025 01:30PM Citi Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

Jul 24, 2025 12:48PM Sarepta Therapeutics (SRPT) PT Lowered to $35 at Jefferies

Jul 24, 2025 11:58AM Sarepta (SRPT) would have to conduct new studies to get back on market, FDA official says - Endpoints

Jul 24, 2025 06:46AM Citi Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (SRPT)

Jul 24, 2025 05:23AM Citi Starts Sarepta Therapeutics (SRPT) at Sell

Jul 23, 2025 09:57AM Freedom Broker Downgrades Sarepta Therapeutics (SRPT) to Hold

Jul 23, 2025 06:05AM BofA Securities Downgrades Sarepta Therapeutics (SRPT) to Underperform

Jul 22, 2025 05:29PM SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Jul 22, 2025 04:00PM ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

Jul 22, 2025 03:36PM SRPT CLASS NOTICE: BFA Law Reminds Sarepta Therapeutics, Inc. Investors of the Pending Securities Fraud Class Action and August 25 Court Deadline

Jul 22, 2025 10:58AM TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)

Jul 22, 2025 10:07AM Sarepta Therapeutics (SRPT) Stock PT Cut in Half at BMO Capital

Jul 22, 2025 09:30AM Sarepta Therapeutics (SRPT) PT Lowered at Piper Sandler After a 'Voluntary Pause Of Elevidys'

Jul 22, 2025 06:37AM H.C. Wainwright Reiterates Sell Rating and $0 Price Target on Sarepta Therapeutics (SRPT)

Jul 22, 2025 05:20AM SRPT INVESTOR ALERT: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Jul 22, 2025 03:52AM Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight

Jul 21, 2025 08:51PM Sarepta pauses U.S. shipments of Duchenne therapy ELEVIDYS

Jul 21, 2025 07:57PM Sarepta Therapeutics (SRPT) Announces Voluntary Pause Of Elevidys Shipments In US

Jul 21, 2025 02:08PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

Jul 21, 2025 09:09AM Sarepta Therapeutics (SRPT) PT Lowered to $18 at Piper Sandler

Jul 21, 2025 07:55AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 07:36AM SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline

Jul 21, 2025 07:04AM Guggenheim Reiterates Buy Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 06:55AM TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)

View More Recent Stories View Older Stories